US2018339014A1PendingUtilityA1
Peptidomimetic macrocycles
Est. expiryJan 14, 2029(~2.5 yrs left)· nominal 20-yr term from priority
C07K 7/64A61K 38/00C12N 2760/16022C07K 7/08A61K 38/10C07K 7/06C07K 7/56C07K 14/005A61P 43/00C07K 7/54A61P 31/16
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease.
Claims
exact text as granted — not AI-modified1 .- 23 . (canceled)
24 . A composition comprising:
a) a peptidomimetic macrocycle comprising an amino acid sequence wherein two amino acids in the amino acid sequence are cross-linked by a crosslinker, wherein the crosslinker comprises a 1, 4-disubstituted triazole and does not comprise a 1, 5-substituted triazole; b) a Cu(I) species; and c) a Ru(II) species.
25 . The composition of claim 1 , wherein the peptidomimetic macrocycle comprises a helix.
26 . The composition of claim 1 , wherein the helix is an alpha helix.
27 . The composition of claim 1 , wherein the peptidomimetic macrocycle comprises a beta turn.
28 . The composition of claim 1 , wherein the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.
29 . The composition of claim 1 , wherein the peptidomimetic macrocycle comprises more than one stabilized secondary structure.
30 . The composition of claim 1 , wherein the crosslinker spans one turn of a secondary structure of the peptidomimetic macrocycle.
31 . The composition of claim 1 , wherein the 1, 5-disubstituted triazole has a formula
and the 1, 4-disubstituted triazole has a formula
wherein L 1 and L 2 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 —]n, each being optionally substituted with R 5 ;
each R 4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;
each K is O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
each R 5 is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;
each R 6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent; and
n is an integer from 1 to 5.
32 . The composition of claim 8 , wherein each L 1 and L 2 is independently an alkylene.
33 . A composition comprising:
a) a peptidomimetic macrocycle comprising:
i) an amino acid sequence wherein two amino acids are cross-linked by a hydrocarbon crosslinker;
ii) an azido moiety; and
iii) an alkyne moiety; and
b) a Ru(II) species.
34 . The composition of claim 33 , wherein the peptidomimetic macrocycle comprises a helix.
35 . The composition of claim 34 , wherein the helix is an alpha helix.
36 . The composition of claim 33 , wherein the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.
37 . The composition of claim 33 , wherein the peptidomimetic macrocycle comprises more than one stabilized secondary structure.
38 . The composition of claim 33 , wherein the cross-linked amino acids are at position i and i+3 of the peptidomimetic macrocycle.
39 . The composition of claim 33 , wherein the crosslinker spans one or two turns of a secondary structure of the peptidomimetic macrocycle.
40 . A composition comprising:
a) a peptidomimetic macrocycle comprising:
i) an amino acid sequence wherein two amino acids are cross-linked by a triazole-containing crosslinker; and
ii) two terminal olefin moieties; and
b) a Cu(I) species.
41 . The composition of claim 40 , wherein the peptidomimetic macrocycle comprises a beta turn.
42 . The composition of claim 40 , wherein the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid.
43 . The composition of claim 40 , wherein the peptidomimetic macrocycle comprises a stabilized secondary structure.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.